Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 2.25mg;  ;   - modified release capsule - 2.25 mg - active: budesonide 2.25mg     excipient: acetyl tributyl citrate ethylcellulose gelatin methacrylic acid copolymer polysorbate 80 purified talc simeticone sugar spheres triethyl citrate

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: acetyl tributyl citrate ethylcellulose gelatin methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc simeticone sugar spheres triethyl citrate - entocort capsules are indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - budesonide - prolonged-release tablet - 9 milligram(s) - corticosteroids acting locally; budesonide

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

tillotts pharma gmbh - budesonide - gastro-resistant capsule, hard - 3 milligram(s) - corticosteroids acting locally; budesonide

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - budesonide, quantity: 9 mg - tablet, modified release - excipient ingredients: stearic acid; lecithin; microcrystalline cellulose; hyprolose; lactose monohydrate; silicon dioxide; magnesium stearate; methacrylic acid copolymer; purified talc; titanium dioxide; triethyl citrate - cortiment prolonged-release tablets are indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis (uc) where 5-asa treatment is not sufficient or not tolerated.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - budesonide 9mg;   - modified release tablet - 9 mg - active: budesonide 9mg   excipient: colloidal silicon dioxide ethanol hyprolose lactose monohydrate lecithin magnesium stearate methacrylic acid copolymer microcrystalline cellulose purified talc stearic acid titanium dioxide triethyl citrate - cortiment prolonged-release tablets are indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis (uc) where 5-asa treatment is not sufficient or not tolerated.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 1 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; macrogol 6000; sodium acid citrate; sodium dihydrogen citrate; sodium bicarbonate; sucralose; povidone; docusate sodium - jorveza is indicated for the treatment of eosinophilic esophagitis (eoe) in adults

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - budesonide - gastro-resistant capsule, hard - 3 milligram(s) - corticosteroids acting locally; budesonide

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 0.5 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; macrogol 6000; sodium acid citrate; sodium dihydrogen citrate; sodium bicarbonate; sucralose; povidone; docusate sodium - jorveza? is indicated for the treatment of eosinophilic oesophagitis (eoe) in adults.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

dr falk pharma new zealand ltd - budesonide 0.5mg - orodispersible tablet - 0.5 mg - active: budesonide 0.5mg excipient: docusate sodium macrogol 6000 magnesium stearate mannitol monosodium citrate povidone sodium acid citrate sodium bicarbonate sucralose - treatment of eosinophilic esophagitis (eoe) in adults (older than 18 years of age).